Friday, 17 Nov 2017

You are here

IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes

With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.

Efficacy of a IL-17A neutralizing antibody secukinumab, and most importantly its role in inhibition of structutal damage, was assessed in FUTURE 5, the largest randomized controlled trial of a biologic conducted to date in PsA.

996 active TNF-experienced (30% of the patients) and TNF-naive PsA patients were randomized 2:2:2:3 to receive sc secukinumab 300 mg with loading dosage (LD),150 mg with LD, 150 mg without LD, or placebo (PBO).

Primary end point of ACR 20 at week 16 was met with significantly better scores in all secukinumab groups 62.6% (300mg), 55.5 (150mg), 59.5% (150 w/out LD) vs 27.4% PBO.

Secondary end point was radiographic progression in peripheral joints (hand/wrist/foot) measured but mTSS at weeks 16 and 24. Significantly greater proportion of pts had no radiographic progression (change from BL in mTSS≤0.5) with secukinumab vs. PBO: 88% (300 mg), 79% (150 mg), 83% (150 mg w/out LD), and 73% (PBO).

Patients who received 150mg w/out LD took longer to achieve response in comparison to 300 mg and 150 mg w/LD, and resolution of dactyitis and enthesitis was not statistically significant in this group.

Adverse event (AE) rates at Wk 16 were 51.8% (300 mg), 52.7% (150 mg), 52.7% (150 mg without LD) and 58.7% (PBO); non-fatal serious AE rates were 2.3%, 3.2%, 1.4%, and 3.0%, respectively. No deaths were reported.

 

In summary, sq secukinumab 300 mg with LD and 150 mg with and without LD inhibited radiographic structural progression and provided rapid and clinically significant improvements in the signs, symptoms and physical function of pts with PsA. The safety profile was consistent with that previously reported with no new safety signals identified.

Add new comment

More Like This

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when MTX is used in rheumatoid arthritis. (Citation source https://buff.ly/2i9qizC)

Several Agents Score on Radiographic Progression in Psoriatic Arthritis

Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.

Novartis Features Secukinumab Data at ACR 17

Novartis has announce it will present its long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting

Structural disease progression is a major concern for AS and PsA patients as it may prompt mobility loss - new data to provide further evidence on the efficacy of Cosentyx to reduce structural disease progression.

FDA Approves Simponi Aria for Psoriatic Arthritis and Ankylosing Spondylitis

Janssen Biotech, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).

Tofacitinib Scores in TNF inhibitor Resistant Psoriatic Arthritis

Mease et al has reported in the NEJM the results of a phase 3 trial showing tofacitinib (Tofa) to be significantly more effective than placebo in active psoriatic arthritis (PsA) patients who previously failed to respond to tumor necrosis factor inhibitor (TNFi) therapies.